RGX-314 Gene Therapy Study is a clinical trial for people with a serious eye problem called neovascular age-related macular degeneration (wet AMD). Wet AMD causes vision loss because of new, leaky blood vessels in the eye. Current treatments require frequent eye injections to help prevent losing more sight. RGX-314 is being tested as a possible one-time treatment to make managing wet AMD easier.

This study will check how well RGX-314 works compared to another medicine, ranibizumab, by looking at changes in vision. Around 300 people will join the study, which will have three different groups. To join, you must be 50-89 years old, have a specific vision score, and have had certain eye treatments before. Conditions like other eye diseases, recent heart problems, or past gene therapy treatments could exclude you.

• Participation involves several clinic visits over the study period.
• This is a Phase 2b/3 study, meaning it’s advanced in testing for safety and effectiveness.
• Participants might receive either RGX-314 or the comparison treatment.